SAN FRANCISCO, Nov. 16, 2021 /PRNewswire/ -- The global lateral flow assays market size is expected to reach USD 9.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.0% from 2021 to 2028. Major drivers of the market include an increase in the prevalence of infectious diseases, a rise in government initiatives to curb infectious and chronic diseases, a rise in demand for point of care testing, and strategic mergers and acquisitions.
Key Insights & Findings:
- The outbreak of COVID-19 has created significant demand for lateral flow assays for conducting mass testing in the U.S. and European countries
- However, increasing vaccinations leading to reduced COVID-19 cases in the coming years may hamper the segment growth
- By product, kits and reagents held the largest share in 2020 as they offer easy, effective, and rapid diagnosis of chronic and infectious diseases
- Easy availability of kits and reagents coupled with the launch of new kits by major players are key factors propelling the segment growth
- A smartphone-based lateral flow reader is more convenient due to its ease of use and portability. Thus, it is anticipated to witness significant growth in the near future
- The clinical testing application segment held the largest market share in 2020 owing to an increase in the incidence of infectious diseases, a rise in the pressure to reduce overall healthcare costs, and increasing demand for POC testing devices that can be used in any healthcare setting
- Technological advancements in the healthcare sector, innovation in technology and devices, and an increase in the adoption of POC testing by patients and healthcare professionals are anticipated to fuel the market growth during the forecast period
- The drug development and quality testing segment is anticipated to witness the fastest CAGR throughout the forecast period
- An increase in the use of lateral flow assays for therapeutic drug monitoring has majorly driven the segment growth
- An increase in the availability of antibiotic tests is one of the factors influencing the market growth during the forecast period
- Sandwich assay technique accounted for significant revenue share in 2020 owing to their accuracy, affordability, and ease of use
- Hospitals and clinics are the major end-users of lateral flow assays, thus, accounted for a major share in 2020
- An increase in healthcare expenditure globally has significantly contributed to the growth of the market.
- North America dominated the market in 2020 with the presence of prominent players in the region and high adoption of advanced products by end-users
- Asia Pacific is projected to witness the fastest CAGR throughout the forecast period
Read 176 page market research report, "Lateral Flow Assays Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Benchtop Readers), By Application (Clinical Testing, Veterinary Diagnostics), By Technique, By End-use, By Region, And Segment Forecasts, 2021 - 2028", by Grand View Research
Continuous strategic initiatives undertaken by leading and emerging players to develop and launch advanced products are anticipated to significantly support the market growth. For instance, in January 2021, U.K.-based Sensyne Health launched MagnifEye, a novel smartphone app that utilizes deep machine learning AI to automate the accurate reading of lateral flow diagnostic tests. Additionally, in March 2021, IUL SA, a Spain-based lateral flow products manufacturer, introduced its new lateral flow reader, iPeak+. In addition, a rise in mergers and collaborations by market players is anticipated to facilitate access to novel lateral flow technologies
A rise in the prevalence of infectious diseases, including the outbreak of COVID-19, and an increase in government initiatives to curb COVID-19, HIV, and other communicable diseases are anticipated to create significant demand for lateral flow devices. According to the U.S. Department of Health & Human Services, the U.S. government has formed the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) that works towards preventing, early detection, and responding to new as well as existing risks related to AIDS and HIV.
Grand View Research has segmented the global lateral flow assays market report on the basis of product, application, technique, end use, and region:
- Lateral Flow Assays Product Outlook (Revenue, USD Million, 2017 - 2028)
- Kits & Reagents
- Lateral Flow Readers
- Digital/Mobile Readers
- Benchtop Readers
- Lateral Flow Assays Application Outlook (Revenue, USD Million, 2017 - 2028)
- Clinical Testing
- Infectious Diseases Testing
- COVID-19 Testing
- Mosquito Borne Disease Testing
- Influenza Testing
- Sexually Transmitted Infection Testing
- HIV Testing
- HPV Testing
- Chlamydia Testing
- Gonorrhea Testing
- Syphilis Testing
- Others
- Hepatitis
- Tuberculosis
- Others
- Cardiac Marker Testing
- Troponin I and T Testing
- CK-MB Testing
- BNP and NT-proBNP Testing
- Myoglobin Testing
- D-Dimer Testing
- Others
- Pregnancy & Fertility Testing
- Pregnancy Testing
- Fertility Testing
- Cholesterol Testing/Lipid Profile Testing
- Drugs of Abuse Testing
- Others
- Veterinary Diagnostics
- Food safety & Environment Testing
- Drug Development & Quality Testing
- Lateral Flow Assays Technique Outlook (Revenue, USD Million, 2017 - 2028)
- Sandwich Assays
- Competitive Assays
- Multiplex Detection Assays
- Lateral Flow Assays End-use Outlook (Revenue, USD Million, 2017 - 2028)
- Hospitals & Clinics
- Diagnostic Laboratories
- Home Care
- Pharmaceutical & Biotechnology Companies
- Others
- Lateral Flow Assays Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players of Lateral Flow Assays Market
- Abbott
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific, Inc.
- Biomerieux SA
- Bio-rad Laboratories, Inc.
- Perkinelmer, Inc.
- Quidel Corporation
- Merck KGAA
- Hologic, Inc.
- Becton, Dickinson and Company
- Danaher Corporation
- Siemens Healthineers
- Qiagen N.V.
Check out more studies related to diagnostic types, conducted by Grand View Research:
- Veterinary Diagnostics Market–The global veterinary diagnostics market size was valued at USD 6.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.5% from 2021 to 2028.
- Rapid Medical Diagnostic Kits Market–The global rapid medical diagnostic kits market size was valued at USD 13.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.4% from 2021 to 2028.
- Paper Diagnostics Market–The global paper diagnostics market size was estimated at USD 5.69 billion in 2017. It is poised to witness a CAGR of 8.0% during the forecast period.
Browse through Grand View Research's coverage of the Global Clinical Diagnostics Industry.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
SOURCE Grand View Research, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=IO77561&Transmission_Id=202111160435PR_NEWS_USPR_____IO77561&DateId=20211116)
Share this article